News

Lexington Begins HeartSentry Clinical Trial

Trial designed to study safety and effectiveness for a non-invasive diagnostic device for cardiovascular health management VANCOUVER, British Columbia, Feb. 20, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce commencement of its clinical trial and first patient enrollment.  These clinical studies are designed to measure

Read More

Lexington Delivers 1st Generation HeartSentry for Clinical Trials

Device completes software, mechanical and electrical tests in preparation for human study VANCOUVER, BRITISH COLUMBIA – February 13, 2018 – Lexington Biosciences, Inc. (CSE: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to advise that its HeartSentry 1st generation product has successfully passed all requisite bench tests in preparation for

Read More

Lexington Receives Approval to Commence Clinical Study

Lexington Biosciences is pleased to announce its recent application for Institutional Review Board (“IRB”) approval of its pilot clinical study at Diablo Clinical Research has been approved. 

Lexington Completes IRB Submission in Preparation for Clinical Study

Another milestone achieved as the Company moves towards HeartSentry human trials Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce it has completed its requisite documentation and submitted an application for Institutional Review Board (“IRB”) approval of its pilot clinical study. In preparation for commercialization of the

Read More

Lexington Biosciences Announces Exercise of Warrants

VANCOUVER, British Columbia, Jan. 11, 2018 — Lexington Biosciences, Inc. (CSE:LNB) (OTCQB:LXGTF) (the “Company” or “Lexington”), a development-stage medical device company, is pleased to announce that 5,497,500 share purchase warrants which were issued on November 24, 2016 and December 20, 2016 have been exercised on or before December 20, 2017 at a price of $0.30 per warrant

Read More

Lexington Biosciences Comments on Recent Trading Activity

VANCOUVER, BC–(Nov 1, 2017) – Lexington Biosciences, Inc. (CSE: LNB) (CSE: LNB.CN) (CNSX: LNB) (OTCQB: LXGTF) (the “Company” or “Lexington“) is issuing this press release at the request of the OTC Markets Group Inc. On October 17, 2017, the Company’s management became aware of certain promotional materials that were published by Techstock Insider that were purportedly paid for by

Read More

What Is Endothelial Function And Why Is It Important To My Health?

— by Jonathan Maltz Almost daily, my Google News stream is filled with articles about a new medical study that some food or medication that was once thought good for heart health is now to be avoided. I understand why many people feel confused and disoriented by the constant state of flux of dietary and

Read More

1 2

Archives

Categories

Newsletter Updates

If you haven’t already done so, signup here to receive future editions and the latest company news direct to your inbox.

Latest News